In addition, a genetic sub-study of the PLATO trial stated that another antiplatelet, ticagrelor, showed better efficacy in managing acute coronary syndromes than clopidogrel despite the CYP2C19 genotype [46]. Here, CYP2C19 is linked to acute coronary syndrome.